ES2124800T3 - Empleo de leflunomida para la inhibicion de interleuquina 1 beta. - Google Patents

Empleo de leflunomida para la inhibicion de interleuquina 1 beta.

Info

Publication number
ES2124800T3
ES2124800T3 ES94100013T ES94100013T ES2124800T3 ES 2124800 T3 ES2124800 T3 ES 2124800T3 ES 94100013 T ES94100013 T ES 94100013T ES 94100013 T ES94100013 T ES 94100013T ES 2124800 T3 ES2124800 T3 ES 2124800T3
Authority
ES
Spain
Prior art keywords
interleukin
leflunomide
beta inhibition
beta
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94100013T
Other languages
English (en)
Spanish (es)
Inventor
Klaus Ulrich Dr Weithmann
Robert Ryder Dr Bartlett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2124800T3 publication Critical patent/ES2124800T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
ES94100013T 1993-01-08 1994-01-03 Empleo de leflunomida para la inhibicion de interleuquina 1 beta. Expired - Lifetime ES2124800T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4300277 1993-01-08

Publications (1)

Publication Number Publication Date
ES2124800T3 true ES2124800T3 (es) 1999-02-16

Family

ID=6477853

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94100013T Expired - Lifetime ES2124800T3 (es) 1993-01-08 1994-01-03 Empleo de leflunomida para la inhibicion de interleuquina 1 beta.

Country Status (8)

Country Link
US (1) US5556870A (cg-RX-API-DMAC7.html)
EP (1) EP0607775B1 (cg-RX-API-DMAC7.html)
JP (1) JPH06234635A (cg-RX-API-DMAC7.html)
AT (1) ATE174218T1 (cg-RX-API-DMAC7.html)
DE (1) DE59407413D1 (cg-RX-API-DMAC7.html)
DK (1) DK0607775T3 (cg-RX-API-DMAC7.html)
ES (1) ES2124800T3 (cg-RX-API-DMAC7.html)
GR (1) GR3029491T3 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5721277A (en) * 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
DE19711800A1 (de) * 1997-03-21 1998-09-24 Hoechst Ag Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
EP0987256B1 (de) * 1997-08-08 2001-10-17 Aventis Pharma Deutschland GmbH Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid
US7691890B2 (en) 1998-03-11 2010-04-06 James W. Williams Anti-viral uses of leflunomide products
ATE382349T1 (de) * 1998-03-11 2008-01-15 Williams James W Antivirale verwendungen von leflunomid produkten
DE19847823A1 (de) 1998-10-16 2000-04-20 Aventis Pharma Gmbh Substituierte Thiadiazolsulfonamide
DE19860802A1 (de) * 1998-12-30 2000-10-26 Virgene Pharmaceuticals Ag Herstellung eines Mittels gegen Hepatitis B-, HI-, Paramyxo und Orthomyxo-Viren
JP2003516351A (ja) * 1999-11-30 2003-05-13 パーカー ヒューズ インスティテュート コラーゲン誘導血小板凝集阻害剤
US6589992B2 (en) 1999-11-30 2003-07-08 Parker Hughes Institute Inhibiting collagen-induced platelet aggregation
EP1473035A1 (en) * 2000-02-15 2004-11-03 Teva Pharmaceutical Industries Ltd. Leflunomide of high purity
CA2400290A1 (en) 2000-02-15 2001-08-23 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
LT2282778T (lt) * 2008-04-29 2017-06-26 Pharnext Nauji terapijos būdai, gydant alzheimerio ligą ir susijusius sutrikimus per angiogenezės moduliaciją
US10813917B2 (en) 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
WO2011072216A2 (en) * 2009-12-11 2011-06-16 The Johns Hopkins University Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
ES2591355T3 (es) * 2010-08-24 2016-11-28 Algiax Pharmaceuticals Gmbh Uso novedoso de leflunomida y malononitrilamidas
JP6917375B2 (ja) * 2015-09-01 2021-08-11 ザ・ブロード・インスティテュート・インコーポレイテッド 血液がんの治療または予防に有用な化合物および方法
EP3544604A4 (en) * 2016-11-23 2020-07-22 Ramot at Tel-Aviv University Ltd. METHOD AND COMPOSITIONS FOR TREATING DISEASES RELATING TO CORTICO-HIPPOCAMPAL HYPERACTIVITY

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854439A1 (de) * 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5494911A (en) * 1990-05-18 1996-02-27 Hoechst Aktiengesellschaft Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use
DE69132470D1 (de) * 1990-08-06 2000-12-21 Chiron Corp Verfahren zum nachweis von cytokinkonvertasehemmern
WO1992016226A1 (en) * 1991-03-19 1992-10-01 Smithkline Beecham Corporation Il-1 inhibitors
WO1995003297A1 (en) * 1993-07-21 1995-02-02 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease

Also Published As

Publication number Publication date
JPH06234635A (ja) 1994-08-23
US5556870A (en) 1996-09-17
EP0607775B1 (de) 1998-12-09
DE59407413D1 (de) 1999-01-21
DK0607775T3 (da) 1999-08-16
GR3029491T3 (en) 1999-05-28
ATE174218T1 (de) 1998-12-15
EP0607775A3 (cg-RX-API-DMAC7.html) 1994-08-31
EP0607775A2 (de) 1994-07-27

Similar Documents

Publication Publication Date Title
ES2124800T3 (es) Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
PT809636E (pt) Isoxazoles substituidos utilizaveis para o tratamento de inflamacoes
ATE156482T1 (de) 1,4,5-triphenyl-pyrazolverbindungen zur behandlumg von entzündungen und entzündungsverwandten störungen
KR100344712B1 (ko) 알러지성및염증성질환의치료에유용한화합물
ES2124801T3 (es) Empleo de leflunomida para la inhibicion del factor de necrosis de tumores alfa.
ATE383167T1 (de) Zusammensetzungen welche dna zerstoerende agentien und p53 enthalten
BR9406746A (pt) Composto processo para sua preparaçao preparado farmacêutico uso de um composto processo para a obtençao da inibiçao de trombina em um organismo humano ou animale fragmento estrutural
BR9502471A (pt) Composto de guanidina processo para preparar um composto de guanidina composição farmaceutica uso de um composto de guanidina método para o tratamento profilático ou terapêutico de doenças e processo para preparar uma composição farmacêutica
DK0607777T3 (da) Anvendelse af leflunomid til inhibering af interleukin 8
BR9304780A (pt) Composto, processo para preparar o composto, composição farmacêutica e uso
ES556474A0 (es) Procedimiento y aparato para enfriar y para el sucesivo tratamiento de clinker caliente de cemento blanco
GR3029492T3 (en) Use of leflunomid for the inhibition of interleukin 1 alpha.
LV10391A (lv) Alkilfosforskabes savienojumu izmantosana psoriazes tipa slimibu arstesanai
DK149590C (da) Analogifremgangsmaade til fremstilling af 2-aryl-3,4-diaza-bicyclo(4,1,0)hepten-(2)-on-(5)-forbindelser
BR9202049A (pt) Antibioticos de beta-lactama,compostos,processo para a sua preparacao,aplicacao de um composto,processo para tratar doencas de infeccoes e agente para o tratamento de uma doenca de infeccao
ITRM940322A0 (it) "composizione farmaceutica contenente carbazolone per il trattamento di emicrania e disturbi psicotici e relativo metodo di preparazione edapplicazione".
PT799039E (pt) Utilizacao de agentes anivirais de aminopurina para o tratamento e profilaxia de infeccoes latentes pelo virus do herpes
TR23391A (tr) Yeni tiofen bilesikleri ve bunlarin hazirlanmasi
SE9201188D0 (sv) Ny anvaendning
DK4389A (da) Isoxazoler med nootrop virkning
BR9304018A (pt) Processo para o tratamento agroquimico de pastos
BR9201771A (pt) Compostos,derivado de amino acidos,processo para sua fabricacao,medicamento,aplicacao do mencionado derivado e processo para tratar ou prevenir infeccoes viais
SE9101340D0 (sv) Agents for preventing or treating bacterial diseases of fishes
LV5180A3 (lv) Preparats "etokans" teju kunga un zarnu slimibu arstesanai un profilaksei
NO932596D0 (no) Sammensetning og farmsoeytisk forbindelse for behandling av "kalsium-oksalat-sten"-sykdom

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 607775

Country of ref document: ES